Clinical trials: sponsored by Eisai Inc.
Solid Tumors
A Study of E7130 in Participants With Solid Tumors
The primary objective of this study is to evaluate the tolerability and safety profile of E7130 in participants with solid tumors.
- Trial name
- NCT03444701
- Testing
- E7130
- Where
- 9 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Eisai Co., Ltd.
Tumors
Phase 1 Study of E7090 in Subjects With Solid Tumor
This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be conducted in 2 parts: 1. Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects…
- Trial name
- NCT02275910
- Testing
- E7090
- Where
- 18 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer's Disease
A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease
The primary objective of this study is to develop and validate claims-based algorithms to identify intracerebral hemorrhage >1 cm in diameter, ensuring differentiation from amyloid-related imaging abnormality-microhemorrhage and…
- Trial name
- NCT07723950
- Testing
- No intervention
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Eisai Inc.
Epilepsies, Myoclonic, Drug Resistant Epilepsy
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.
- Trial name
- NCT04457687
- Testing
- Lorcaserin
- Where
- 22 sites in United States, Canada
- Sponsor
- Eisai Inc.
Endometrial Neoplasms, Neoplasms
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386…
- Conditions
- Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
- Trial name
- NCT04008797
- Testing
- E7386, Lenvatinib, Doxorubicin
- Where
- 106 sites in United States, Canada and 8 more
- Volunteers
- 301 people
- Sponsor
- Eisai Inc.
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm…
- Trial name
- NCT07762092
- Testing
- No Intervention
- Where
- 17 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Solid Neoplasms
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
The primary purpose of the study is to evaluate safety and tolerability of E7389 liposomal formulation (E7389-LF) in combination with nivolumab and to determine the recommended Phase 2 dose (RP2D) in Phase 1b part and to evaluate…
- Trial name
- NCT04078295
- Testing
- E7389-LF, Nivolumab
- Where
- 19 sites in Japan
- Volunteers
- 125 people
- Sponsor
- Eisai Co., Ltd.
Metastatic Malignant Neoplasm in the Adult Brain, Primary Brain Tumor
Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
This pilot trial studies the brain concentration of eribulin mesylate in treating patients with primary or metastatic brain tumors.
- Trial name
- NCT02338037
- Testing
- Therapeutic Conventional Surgery, Biopsy, Eribulin Mesylate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Alzheimer's Disease
An Observational Study of LEQEMBI in Routine Clinical Practice in Taiwan
The primary purpose of this study is to describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities (ARIA)-oedema/effusion (ARIA-E), ARIA-microhemorrhage and haemosiderin deposit…
- Trial name
- NCT07869264
- Testing
- No Intervention
- Where
- 12 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Eisai Taiwan Inc.
Adenoid Cystic Carcinoma, Salivary Gland Cancer
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
The purpose of this study is to see if the study drugs, lenvatinib and pembrolizumab, are effective in treating advanced Adenoid Cystic Carcinoma (ACC) or other salivary gland cancers that have come back and/or spread to other…
- Trial name
- NCT04209660
- Testing
- Lenvatinib, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Alzheimers Disease
A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease
The primary purpose of this study is to evaluate the efficacy of LEQEMBI in participants with early Alzheimer's disease (AD) indicated per Canada Product Monograph (APOE4 non-carriers and heterozygotes; indicated population)…
- Trial name
- NCT07864623
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Eisai Inc.
Hepatocellular Carcinoma
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
This study will examine the effects of a six-month regimen of neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma…
- Trial name
- NCT05171335
- Testing
- Lenvatinib, Transcatheter Arterial Chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Methodist Hospital Research Institute
Brain Metastases, Tumor
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases.
- Trial name
- NCT05064280
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- M.D. Anderson Cancer Center
Healthy Volunteers
A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants
The primary purpose of this study is to assess potential drug-drug interactions of E2086 when coadministered orally with Itraconazole, Carbamazepine, Midazolam, Dextromethorphan, Bupropion, or Combined Oral Contraceptives in…
- Trial name
- NCT07766369
- Testing
- E2086
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Early Alzheimer's Disease
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical…
- Trial name
- Clarity AD (NCT03887455)
- Testing
- Lecanemab IV, Lecanemab SC
- Where
- 247 sites in United States, Australia and 12 more
- Volunteers
- 1,906 people
- Sponsor
- Eisai Inc.
Carcinoma, Renal Cell
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in…
- Trial name
- NCT04736706
- Testing
- Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab
- Where
- 262 sites in United States, Australia and 33 more
- Volunteers
- 1,688 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular
Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)
This observational study will use existing real-world data from routine clinical care to describe patients with uHCC who received lenvatinib.
- Trial name
- NCT07849660
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Eisai Inc.
Nocturia
How Well and Safely Does Lemborexant Work for People Who Wake up at Night to Urinate (LENS)
Nocturia is defined by doctors as getting up one or more times a night to use the bathroom, where you were asleep before going to use the washroom and then going back to sleep afterward.
- Trial name
- LENS (NCT07840638)
- Testing
- Lemborexant tablets
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University of Alberta
Hepatic Impairment
Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants
The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of tasurgratinib after a single dose administration.
- Trial name
- NCT04271488
- Testing
- Tasurgratinib
- Where
- 8 sites in Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Alzheimer's Disease
A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
The primary purpose of this study is to evaluate the safety of lecanemab-irmb in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition…
- Trial name
- NCT07821658
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 6,700 people
- Sponsor
- Eisai Inc.